DEF 14A: 10x Genomics Sets Date for 2024 Annual Stockholders Meeting, Proposes Bylaw Amendment

10x Genomics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, including proposals for director election, auditor ratification, bylaw amendment, and executive compensation advisory vote.

Summary

• 10x Genomics will hold its 2024 Annual Meeting of Stockholders virtually on June 11, 2024, at 1:30 p.m. PDT.
• Stockholders will vote on four proposals: electing a Class II director, ratifying Ernst & Young LLP as the independent accounting firm, approving an amendment to the bylaws, and approving, on an advisory basis, executive compensation.
• The board recommends voting FOR the director nominee and FOR each of the other proposals.
• The record date for determining stockholders eligible to vote is April 15, 2024.
• The company has engaged Morrow Sodali LLC to assist in the solicitation of proxies for a fee of $15,000.
• The board has determined that five of the seven directors are independent.
• The annual cash retainer for non-employee directors is $50,000, with additional retainers for committee chairs and members.
• The board is asking stockholders to approve an amendment to the bylaws to allow the board to amend the bylaws without requiring stockholder approval.
• The company's revenue for the year ended December 31, 2023, was $618.7 million, representing a 20% year-over-year growth rate.
• The company sold more than 250 Xenium instruments in the first year of launch.
• The company surpassed 7,000 peer-reviewed publications citing 10x technologies, a 58% increase year-over-year.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting revenue growth and successful product launches. However, it is a standard proxy statement, so the sentiment is moderate.

Positives

• The company experienced strong revenue growth of 20% in 2023.
• Adoption of the Xenium platform has been successful, with over 250 instruments sold in the first year.
• The number of publications citing 10x Genomics technologies has significantly increased.
• The company ended the year in a strong financial position with positive free cash flow in the quarter ending December 31, 2023.
• The company has implemented stock ownership guidelines for executives and directors.

Negatives

• The document does not explicitly state any negatives.

Risks

• The document does not explicitly state any risks.

Future Outlook

The company aims to effectively drive sustainable, long-term global growth and execute its long-term strategy.

Management Comments

• Serge Saxonov, Chief Executive Officer and Director: 'I would like to take this opportunity to thank our stockholders for their continued support.'

Industry Context

The document provides information relevant to investors in the life sciences and biotechnology sectors, particularly those interested in genomics companies.

Comparison to Industry Standards

• The document mentions a peer group of companies used for compensation benchmarking, including ACADIA Pharmaceuticals Inc., Guidewire Software, Inc., NovoCure Limited, Adaptive Biotechnologies Corporation, Insulet Corporation, Penumbra, Inc., Alteryx, Inc., Invitae Corporation, Repligen Corporation, Azenta, Inc., Maravai Lifesciences Holdings, Inc., Sotera Health Company, Coupa Software Incorporated, Natera, Inc., Twist Bioscience, Inc., Exact Sciences Corporation, NeoGeonomics, Inc., Veracyte, Inc., Guardant Health, Inc., and Nevro Corp.
• The company's revenue growth of 20% is a key metric for comparison against industry peers.
• The document notes that the CEO's target total direct compensation is near the 50th percentile of the peer group, with base salary and total target cash compensation near the 25th percentile.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The proposals directly impact shareholder voting rights and corporate governance.
• Employees: Executive compensation and benefit plans are discussed, affecting employee morale and retention.
• Customers: The company's performance and strategic direction impact its ability to innovate and provide value to customers.

Next Steps

• Stockholders are urged to vote promptly via regular mail, online, or by telephone.
• The company will file a report on Form 8-K within four business days after the 2024 Annual Meeting to publish the final voting results.

Key Dates

Keywords

proxy statement, annual meeting, executive compensation, board of directors, stockholders, corporate governance, 10x Genomics